Lilah M Besser1, Irene Litvan2, Sarah E Monsell3, Charles Mock4, Sandra Weintraub5, Xiao-Hua Zhou6, Walter Kukull7. 1. National Alzheimer's Coordinating Center, University of Washington, 4311 11th Ave NE, Suite 300, Seattle, WA, 98105, USA. Electronic address: lmbesser@uw.edu. 2. University of California San Diego, Department of Neurosciences, National Parkinson Foundation Movement Disorder Center of Excellence, 8950 Villa La Jolla Drive, Suite C112, La Jolla, CA, 92037, USA. Electronic address: ilitvan@ucsd.edu. 3. National Alzheimer's Coordinating Center, University of Washington, 4311 11th Ave NE, Suite 300, Seattle, WA, 98105, USA. Electronic address: smonsell@uw.edu. 4. National Alzheimer's Coordinating Center, University of Washington, 4311 11th Ave NE, Suite 300, Seattle, WA, 98105, USA. Electronic address: cmock@u.washington.edu. 5. Cognitive Neurology and Alzheimer's Disease Center, and Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, 320 E Superior, Searle 11-467, Chicago, IL, 60611, USA. Electronic address: sweintraub@northwestern.edu. 6. National Alzheimer's Coordinating Center, University of Washington, 4311 11th Ave NE, Suite 300, Seattle, WA, 98105, USA. Electronic address: azhou@u.washington.edu. 7. National Alzheimer's Coordinating Center, University of Washington, 4311 11th Ave NE, Suite 300, Seattle, WA, 98105, USA. Electronic address: Kukull@uw.edu.
Abstract
INTRODUCTION: No known studies have compared longitudinal characteristics between individuals with incident mild cognitive impairment due to Parkinson's disease (PD-MCI) versus Alzheimer's Disease (AD-MCI). METHODS: We used longitudinal data from the National Alzheimer's Coordinating Center's Uniform Data Set to compare 41 PD-MCI and 191 AD-MCI participants according to their demographics, presence of ≥1 APOE e4 allele, and baseline and change over time in clinical characteristics, neuropsychological test scores, and Clinical Dementia Rating sum of boxes (CDR-SB). Multivariable linear regression models with generalized estimating equations were used to account for clustered data and to test for baseline and longitudinal differences in neuropsychological test scores. RESULTS: PD-MCI and AD-MCI participants differed by many demographic and clinical characteristics. Significantly fewer PD-MCI participants developed dementia over one year. Compared to AD-MCI participants, PD-MCI participants performed better at baseline and over time on a global measure of cognition (Mini Mental State Exam), memory measures (immediate and delayed Logical Memory), and a language measure (Boston Naming Test), and additionally performed better over time on an attention measure (Digit Span Forward), a language measure (Vegetable List), a processing speed measure (Digit Symbol), and an overall measure of memory and functional impairment (CDR-SB). CONCLUSION: Our study provides further evidence that PD-MCI is clinically distinct from AD-MCI and requires different tools for diagnosis and monitoring clinical progression. More importantly, this study suggests that PD-MCI takes longer to convert into dementia than AD-MCI, findings that require replication by other studies.
INTRODUCTION: No known studies have compared longitudinal characteristics between individuals with incident mild cognitive impairment due to Parkinson's disease (PD-MCI) versus Alzheimer's Disease (AD-MCI). METHODS: We used longitudinal data from the National Alzheimer's Coordinating Center's Uniform Data Set to compare 41 PD-MCI and 191 AD-MCI participants according to their demographics, presence of ≥1 APOE e4 allele, and baseline and change over time in clinical characteristics, neuropsychological test scores, and Clinical Dementia Rating sum of boxes (CDR-SB). Multivariable linear regression models with generalized estimating equations were used to account for clustered data and to test for baseline and longitudinal differences in neuropsychological test scores. RESULTS:PD-MCI and AD-MCIparticipants differed by many demographic and clinical characteristics. Significantly fewer PD-MCI participants developed dementia over one year. Compared to AD-MCI participants, PD-MCI participants performed better at baseline and over time on a global measure of cognition (Mini Mental State Exam), memory measures (immediate and delayed Logical Memory), and a language measure (Boston Naming Test), and additionally performed better over time on an attention measure (Digit Span Forward), a language measure (Vegetable List), a processing speed measure (Digit Symbol), and an overall measure of memory and functional impairment (CDR-SB). CONCLUSION: Our study provides further evidence that PD-MCI is clinically distinct from AD-MCI and requires different tools for diagnosis and monitoring clinical progression. More importantly, this study suggests that PD-MCI takes longer to convert into dementia than AD-MCI, findings that require replication by other studies.
Authors: Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre Journal: Mov Disord Date: 2012-01-24 Impact factor: 10.338
Authors: Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub Journal: Mov Disord Date: 2011-06-09 Impact factor: 10.338
Authors: Charles H Adler; John N Caviness; Marwan N Sabbagh; Holly A Shill; Donald J Connor; Lucia Sue; Virgilio G H Evidente; Erika Driver-Dunckley; Thomas G Beach Journal: Acta Neuropathol Date: 2010-09-14 Impact factor: 17.088
Authors: Ann B Sollinger; Felicia C Goldstein; James J Lah; Allan I Levey; Stewart A Factor Journal: Parkinsonism Relat Disord Date: 2009-11-25 Impact factor: 4.891
Authors: Duane L Beekly; Erin M Ramos; William W Lee; Woodrow D Deitrich; Mary E Jacka; Joylee Wu; Janene L Hubbard; Thomas D Koepsell; John C Morris; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2007 Jul-Sep Impact factor: 2.703
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: John N Caviness; Erika Driver-Dunckley; Donald J Connor; Marwan N Sabbagh; Joseph G Hentz; Brie Noble; Virgilio Gerald H Evidente; Holly A Shill; Charles H Adler Journal: Mov Disord Date: 2007-07-15 Impact factor: 10.338
Authors: Elliot Hampsey; Marton Meszaros; Caroline Skirrow; Rebecca Strawbridge; Rosie H Taylor; Lazarus Chok; Dag Aarsland; Ammar Al-Chalabi; Ray Chaudhuri; Jack Weston; Emil Fristed; Aleksandra Podlewska; Olabisi Awogbemila; Allan H Young Journal: BMJ Open Date: 2022-06-06 Impact factor: 3.006
Authors: Anja Ophey; Steffen Wolfsgruber; Sandra Roeske; Alexandra Polcher; Annika Spottke; Lutz Frölich; Michael Hüll; Frank Jessen; Johannes Kornhuber; Wolfgang Maier; Oliver Peters; Alfredo Ramirez; Jens Wiltfang; Inga Liepelt-Scarfone; Sara Becker; Daniela Berg; Jörg B Schulz; Kathrin Reetz; Jennifer Wojtala; Jan Kassubek; Alexander Storch; Monika Balzer-Geldsetzer; Rüdiger Hilker-Roggendorf; Karsten Witt; Brit Mollenhauer; Claudia Trenkwalder; Hans-Ullrich Wittchen; Oliver Riedel; Richard Dodel; Michael Wagner; Elke Kalbe Journal: Alzheimers Dement (Amst) Date: 2021-09-14
Authors: Julia Gallagher; Jacqueline Rick; Sharon X Xie; Pablo Martinez-Martin; Eugenia Mamikonyan; Alice Chen-Plotkin; Nabila Dahodwala; James Morley; John E Duda; John Q Trojanowski; Andrew Siderowf; Daniel Weintraub Journal: J Parkinsons Dis Date: 2021 Impact factor: 5.568